Lisata Therapeutics Completes Marea Merger, Raises $225 Million

What happened

Lisata Therapeutics, Inc. (Nasdaq: LSTA), a Delaware-incorporated pharmaceutical company, acquired Marea Therapeutics, Inc. on September 17, 2026, according to a Form 8-K filed the same day. The deal closed under an Agreement and Plan of Merger dated the same date, with no shareholder vote of Lisata required — the filing states the board unanimously approved the agreement and the transaction.

The structure was a two-step merger: a wholly owned Lisata subsidiary merged into Marea, leaving Marea as a wholly owned Lisata subsidiary, and Marea then merged into a second Lisata subsidiary, which survived. Lisata said the merger is intended to qualify as a tax-free reorganization for U.S. federal income tax purposes.

As consideration, Lisata issued Marea stockholders 1,793,129.0 shares of common stock and 211,365.213 shares of a newly created Series C Non-Voting Convertible Preferred Stock. Each preferred share converts into 1,000 shares of common stock, but only after Lisata stockholders approve the conversion.

On the same day, Lisata entered a Securities Purchase Agreement with investors to sell 150,867.995 additional shares of Series C Preferred Stock for about $225 million. That private placement is expected to close September 18, 2026. Lisata also signed registration rights agreements covering resale of the shares issued in the merger and sold in the financing, and lock-up agreements imposing a 180-day restriction on sales by certain officers, directors and stockholders.

How ownership shifts

The filing lays out the resulting ownership in detail. Immediately after the merger but before the financing, and assuming the Series C Preferred Stock converts, Lisata's pre-transaction equityholders would hold approximately 3.87% of the outstanding common stock and Marea's former equityholders approximately 96.13%, on a fully diluted basis using the parties' implied equity values.

After the financing, and again assuming conversion of both the merger-related preferred shares and the PIPE securities, Lisata's pre-transaction stockholders would hold approximately 2.39%, Marea's former equityholders approximately 59.54%, and the new investors approximately 38.07%.

Marea stock options were assumed by Lisata and converted into options to purchase Series C Preferred Stock. The filing states those options carry exercise restrictions until Lisata stockholders approve the matters being put to them. Lisata's directors and officers, plus affiliated entities, representing about 4.3% of pre-transaction shares, signed support agreements committing to vote for those matters at a stockholders' meeting to be held.

What this means

An 8-K is a current report: a public company must file one with the SEC within four business days of certain major events. The numbered "items" in the filing are the categories of event being disclosed. This one covers seven of them at once — a material agreement (1.01), a completed acquisition (2.01), an unregistered sale of equity (3.02), a director or officer change (5.02), amended charter or bylaws (5.03), Regulation FD disclosure (7.01) and exhibits (9.01) — which is why one filing describes a merger, a financing and governance changes together.

Preferred stock is a class of equity that sits above common stock in priority, usually carries no voting rights, and here is explicitly non-voting. Convertible means each preferred share can be exchanged for common stock at a set ratio — in this case 1,000 common shares per preferred share. The reason conversion is delayed: Nasdaq rules require a shareholder vote before a company issues enough stock to change control, because the incoming holders would otherwise receive their shares without existing owners having a say. The filing names the votes Lisata must hold: approving the conversion, approving the "change of control" under Nasdaq Listing Rules 5110 and 5635(b), and possibly amending the charter to authorize more common shares or to effect a reverse stock split to stay in compliance with Nasdaq listing standards.

"Unregistered sale of equity" means Lisata sold stock without registering it with the SEC first. That is permitted when the sale is a private placement to a limited set of investors rather than a public offering — the filing cites Section 4(a)(2) of the Securities Act of 1933, which exempts transactions by an issuer not involving any public offering. In exchange, the buyers get registration rights: the company must file a resale registration statement so those shares can eventually be sold publicly. A registration statement is the document that makes a security freely tradable.

A lock-up agreement bars insiders and major holders from selling for a set period — 180 days here — to prevent a wave of sales right after a deal closes. Because the deal and the financing are largely stock, the practical effect is that Marea's former holders and the new investors control the large majority of the post-close company on a converted basis, while Lisata's legacy holders own a small single-digit percentage. The filing does not state why Lisata pursued the transaction or why Marea agreed; it sets out the terms only. The company says it will file a proxy statement for the shareholder meeting and a Form 8-K/A with Marea's financial statements and pro forma figures no later than November 12, 2026.

The stock

Lisata's common stock closed at $1.74 on the event date, up 18.37% from the prior close of $1.47, according to the price data provided. Volume was 3,035,900 shares, about 12.4 times the average volume of 244,545 and roughly three standard deviations above the norm. The sources provided do not state why the stock moved; the filing itself does not attribute the price or volume to any specific cause.